Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

1-Year Data Analysis from a Cancer Center Molecular Tumor Board Dedicated to Clonal Hematopoiesis

Blood (2023) 142 (Supplement 1): 1322.

https://doi.org/10.1182/blood-2023-186721

Published: 2023

Journal Articles

The ALK-OBS Trial: Results of a Multicenter Prospective Study Assessing the Prognostic Value of New Markers in Adults with ALK-Positive ALCL Treated By CHOEP: A Lysa Study

Blood (2022) 140 (Supplement 1): 3680–3682.

https://doi.org/10.1182/blood-2022-170841

Published: 2022

Journal Articles

Reduced Venetoclax Exposition to Seven Days of Azacitidine Is Efficient in Treatment-Naïve Patients with Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 537–538.

https://doi.org/10.1182/blood-2022-165464

Published: 2022

Journal Articles

Therapy Related Myeloid Neoplasms Following PARP Inhibitors : Real-Life Experience

Blood (2022) 140 (Supplement 1): 12335–12338.

https://doi.org/10.1182/blood-2022-163478

Published: 2022

Journal Articles

An unusual myelofibrosis

Véronique Vergé, Peggy Dartigues

Blood (2022) 140 (13): 1570.

https://doi.org/10.1182/blood.2022015663

Published: 2022

Journal Articles

Molecular Profiling Feasibility on Cell-Free Tumoral DNA in Relapse/Refractory (R/R) Multiple Myeloma (MM) Patients Screened for Phase I Trials

Cyril Quivoron, Helene Lecourt, Jean-Marie Michot, Julien Lazarovici, Julien Rossignol, David Ghez, Veronique Vergé, Veronique Saada, Alina Danu, Vincent Ribrag

Blood (2021) 138 (Supplement 1): 3763.

https://doi.org/10.1182/blood-2021-149369

Published: 2021

Journal Articles

High Incidence of TP53 and Epigenetic Modifying Oncogenes Mutations in a Large Cohort of Patients Enrolled in Phase 1 Clinical Trials for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Cyril Quivoron, PhD, Jean-Marie Michot, MD, Valérie Camara-clayette, PhD, Alina Danu, MD, Julien Lazarovici, MD, Clementine Sarkozy, MD PhD, David Ghez, MD PhD, Julien Rossignol, MD PhD, Capucine Baldini, MD, Patricia Martin-Romano, MD PhD, Helene Lecourt, Veronique Vergé, MD, Andrea Varga, MD, Sophie Cotteret, MD PhD, Peggy Dartigues-Cuillères, MD, Christophe Massard, MD PhD, Vincent Ribrag, MD

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-136114

Published: 2020

Journal Articles

Is Molecular Characterization Useful for Targeted Therapy Orientation in Patients with Relapsed or Refractory DLBCL Included in Early Phase Clinical Trials?

Jean-Marie Michot, MD, Valérie Camara-Clayette, PhD, Cyril Quivoron, PhD, Alina Danu, MD, Julien Lazarovici, MD, David Ghez, MD PhD, Julien Rossignol, MD PhD, Capucine Baldini, MD, Patricia Martin-Romano, MD PhD, Clementine Sarkozy, MD PhD, Andrea Varga, MD, Helene Lecourt, Veronique Vergé, MD, Sophie Cotteret, MD PhD, Peggy Dartigues-Cuillères, MD, Christophe Massard, MD PhD, Vincent Ribrag, MD

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-136134

Published: 2020

Journal Articles

COVID-19–induced atypical pulmonary lymphocytes

Véronique Vergé, Ranya Soufan

Blood (2020) 136 (19): 2241.

https://doi.org/10.1182/blood.2020007613

Published: 2020

Journal Articles

Comparative Study of Tumor Biopsy and Ctdna to Support Patient Selection in Phase I Trials: The Gustave Roussy Single Center Experience in Aggressive B-Cell Lymphomas

Anthony Tarabay, MD, Jean-Marie Michot, MD, Anne Aupérin, Julien Lazarovici, Julien Rossignol, MD PhD, David Ghez, MD PhD, Peggy Dartigues-Cuillères, MD, Veronique Vergé, Vincent Ribrag, MD, Christophe Massard, Valérie Camara-clayette

Blood (2019) 134 (Supplement_1): 1496.

https://doi.org/10.1182/blood-2019-127170

Published: 2019

Journal Articles

Feasibility and Benefit of Molecularly-Informed Enrollment into Early Phase Clinical Trials for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Blood (2018) 132 (Supplement 1): 4110.

https://doi.org/10.1182/blood-2018-99-110852

Published: 2018

Journal Articles

Non-Effectiveness of Using RICE Post RDHAP or RDHAP Post RICE after Failure of First Line Salvage Therapy in DLBCL Patients Who Are Eligible for ASCT

Tony Ibrahim, MD MSc, Tarek Assi, Julien Lazarovici, MD, Maxime Annereau, PharmD, David Ghez, MD PhD, Jean-Marie Michot, MD, Julia Arfi-Rouche, Julien Rossignol, MD PhD, Veronique Vergé, Jacques Bosq, Peggy Dartigues-Cuillères, MD, Alina Danu, MD, Vincent Ribrag, MD

Blood (2018) 132 (Supplement 1): 4226.

https://doi.org/10.1182/blood-2018-99-117444

Published: 2018

Journal Articles

Feasibility and Benefit of Molecularly-Informed Enrollment into Personalized Therapies or Early Phase Trials for Patients with Relapsed or Refractory Multiple Myeloma

Tarek Assi, Jean-Marie Michot, MD, Toni Ibrahim, MD MSc, Fabien Le Bras, Karim Belhadj, Julien Lazarovici, MD, David Ghez, MD PhD, Julien Rossignol, MD PhD, Veronique Vergé, Julia Arfi-Rouche, Sophie Cotteret, Christophe Massard, Jean-Charles Soria, Alina Danu, MD, Vincent Ribrag, MD

Blood (2018) 132 (Supplement 1): 2001.

https://doi.org/10.1182/blood-2018-99-111050

Published: 2018

Journal Articles

Dose-Adjusted Rituximab Mini-CYVE (CYtarabine bolus, VEpeside and dexamethasone) for Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Not Eligible for High Dose Therapy

Yolla EL Dakdouki, Jean-Marie Michot, MD, Julien Lazarovici, MD, Khalil Saleh, MD, David Ghez, MD PhD, Claude Chahine, MD, Loic Verlingue, Christophe Willekens, MD, Veronique Vergé, Christophe Ferme, MD, Alina Danu, MD, Vincent Ribrag, MD

Blood (2017) 130 (Supplement 1): 2847.

https://doi.org/10.1182/blood.V130.Suppl_1.2847.2847

Published: 2017

Journal Articles

BRAF V600E Targetable Mutation in Relapsed/Refractory Multiple Myeloma (R/R MM) Patients: A High Incidence in R/R MM Detected Using Cell Sorting Screening

Alina Danu, MD, Sophie Cotteret, PhD, Ludovic Lacroix, Véronique Saada, PharmD, Véronique Vergé, MD, Nathalie Auger, Julien Lazarovici, MD, Edith Carton, Jonathan Farhi, Khalil Saleh, MD, David Ghez, PhD MD, Claude Chahine, MD, Jean-Marie Michot, MD, Vincent Ribrag, MD

Blood (2016) 128 (22): 5638.

https://doi.org/10.1182/blood.V128.22.5638.5638

Published: 2016

NARROW

1-Year Data Analysis from a Cancer Center Molecular Tumor Board Dedicated to Clonal Hematopoiesis

The ALK-OBS Trial: Results of a Multicenter Prospective Study Assessing the Prognostic Value of New Markers in Adults with ALK-Positive ALCL Treated By CHOEP: A Lysa Study

Reduced Venetoclax Exposition to Seven Days of Azacitidine Is Efficient in Treatment-Naïve Patients with Acute Myeloid Leukemia

Therapy Related Myeloid Neoplasms Following PARP Inhibitors : Real-Life Experience

An unusual myelofibrosis

Molecular Profiling Feasibility on Cell-Free Tumoral DNA in Relapse/Refractory (R/R) Multiple Myeloma (MM) Patients Screened for Phase I Trials

High Incidence of TP53 and Epigenetic Modifying Oncogenes Mutations in a Large Cohort of Patients Enrolled in Phase 1 Clinical Trials for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Is Molecular Characterization Useful for Targeted Therapy Orientation in Patients with Relapsed or Refractory DLBCL Included in Early Phase Clinical Trials?

COVID-19–induced atypical pulmonary lymphocytes

Comparative Study of Tumor Biopsy and Ctdna to Support Patient Selection in Phase I Trials: The Gustave Roussy Single Center Experience in Aggressive B-Cell Lymphomas

Feasibility and Benefit of Molecularly-Informed Enrollment into Early Phase Clinical Trials for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Non-Effectiveness of Using RICE Post RDHAP or RDHAP Post RICE after Failure of First Line Salvage Therapy in DLBCL Patients Who Are Eligible for ASCT

Feasibility and Benefit of Molecularly-Informed Enrollment into Personalized Therapies or Early Phase Trials for Patients with Relapsed or Refractory Multiple Myeloma

Dose-Adjusted Rituximab Mini-CYVE (CYtarabine bolus, VEpeside and dexamethasone) for Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Not Eligible for High Dose Therapy

BRAF V600E Targetable Mutation in Relapsed/Refractory Multiple Myeloma (R/R MM) Patients: A High Incidence in R/R MM Detected Using Cell Sorting Screening

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only